NCT00338780View on ClinicalTrials.gov

Trial of Lamivudine Treatment in HBeAg Negative Chronic Hepatitis B Patients (in Asia)

PHASE4CompletedINTERVENTIONAL

Timeline

Start Date

November 30, 2000

Study Completion Date

January 31, 2005

Conditions

Chronic Hepatitis B

Interventions

DRUG

Lamivudine/ Placebo 100mg daily

Trial Locations (1)

Unknown

Cheng Suen Man Shook Hepatitis Center, Institute of Digestive Disease, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong SAR

Sponsors

Collaborators (1)

GlaxoSmithKline

All Listed Sponsors

collaborator

GlaxoSmithKline

INDUSTRY

lead

Chinese University of Hong Kong

OTHER

NCT00338780 - Trial of Lamivudine Treatment in HBeAg Negative Chronic Hepatitis B Patients (in Asia) | Biotech Hunter | Biotech Hunter